JP2022531012A - インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法 - Google Patents

インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法 Download PDF

Info

Publication number
JP2022531012A
JP2022531012A JP2021565743A JP2021565743A JP2022531012A JP 2022531012 A JP2022531012 A JP 2022531012A JP 2021565743 A JP2021565743 A JP 2021565743A JP 2021565743 A JP2021565743 A JP 2021565743A JP 2022531012 A JP2022531012 A JP 2022531012A
Authority
JP
Japan
Prior art keywords
indirubin
dosage form
indigo
polymer
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021565743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531012A5 (enExample
Inventor
デイヴィッドソン，マシュー
サイキ，ジュリー
アンドレアソン，ヨハン
デイビッド ファベロ，マイケル
ベンジャミン グリーン，マシュー
Original Assignee
アゾーラ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アゾーラ セラピューティクス，インコーポレイテッド filed Critical アゾーラ セラピューティクス，インコーポレイテッド
Publication of JP2022531012A publication Critical patent/JP2022531012A/ja
Publication of JP2022531012A5 publication Critical patent/JP2022531012A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021565743A 2019-05-03 2020-05-01 インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法 Pending JP2022531012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022531012A true JP2022531012A (ja) 2022-07-05
JP2022531012A5 JP2022531012A5 (enExample) 2023-05-30

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565743A Pending JP2022531012A (ja) 2019-05-03 2020-05-01 インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法

Country Status (10)

Country Link
US (3) US20200345645A1 (enExample)
EP (1) EP3962458A1 (enExample)
JP (1) JP2022531012A (enExample)
KR (1) KR20220044435A (enExample)
CN (1) CN114340600A (enExample)
AU (1) AU2020269379A1 (enExample)
CA (1) CA3136081A1 (enExample)
MX (1) MX2021013386A (enExample)
TW (1) TW202106296A (enExample)
WO (1) WO2020227151A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR20240152820A (ko) 2021-11-30 2024-10-22 엔도퀘스트 로보틱스 인코포레이티드 로봇 제어 의료 기기용 힘 전달 시스템
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP2015520241A (ja) * 2012-06-21 2015-07-16 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2016506948A (ja) * 2013-02-06 2016-03-07 大塚製薬株式会社 非晶質なシロスタゾールを含有する固体分散体
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
BR112018071370A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de mesalazina
JP7325753B2 (ja) * 2018-01-18 2023-08-15 慶應義塾 潰瘍性大腸炎治療カプセル剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP2015520241A (ja) * 2012-06-21 2015-07-16 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2016506948A (ja) * 2013-02-06 2016-03-07 大塚製薬株式会社 非晶質なシロスタゾールを含有する固体分散体
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER. RES., vol. Vol.13(1), JPN6024016415, 2007, pages 253 - 259, ISSN: 0005641173 *
IMMUNOLOGICAL MEDICINE, vol. Vol.42(1), JPN6024016410, 29 April 2019 (2019-04-29), pages 16 - 21, ISSN: 0005641176 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 7, JPN6024016416, 2012, pages 1115 - 1125, ISSN: 0005641172 *
YONAGO ACTA MEDICA, vol. 61, JPN6024016411, 2018, pages 128 - 136, ISSN: 0005641175 *
ファルマシア, vol. Vol.52(5), JPN6024016414, 2016, pages 392 - 396, ISSN: 0005641174 *
廃棄物資源循環学会誌, vol. Vol.30(3), JPN6024016412, 2019, pages 168 - 178, ISSN: 0005641177 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用

Also Published As

Publication number Publication date
TW202106296A (zh) 2021-02-16
US20200345645A1 (en) 2020-11-05
CA3136081A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
CN114340600A (zh) 2022-04-12
EP3962458A1 (en) 2022-03-09
AU2020269379A1 (en) 2021-12-02
KR20220044435A (ko) 2022-04-08
MX2021013386A (es) 2022-03-22
WO2020227151A1 (en) 2020-11-12
US20250255820A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
US20250255820A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
JP6843798B2 (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
US5415871A (en) Therapeutic agents
KR20040004638A (ko) 의약 조성물
JP2012514623A (ja) １またはそれ以上のフマル酸エステルを含む医薬組成物
BRPI0608853B1 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
BG106683A (bg) Състави със забавено освобождаване на производни на еритромицин
AU2015326392B2 (en) Pharmaceutical compositions comprising alpelisib
GB2414668A (en) Sustained release delivery system for tetracycline compounds
US20100204333A1 (en) Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
WO2022138717A1 (ja) 経口固形製剤
US20200345691A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US20100272794A1 (en) Pharmaceutical composition of memantine
CN102316864B (zh) 时间治疗药物组合物
JPH04368330A (ja) ペミロラストカリウムの徐放性製剤
KR0184350B1 (ko) 오메프라졸 구강점막 부착 정제 조성물
TW202510861A (zh) 泮托拉唑藥物組合物、其製備方法及用途
JP2021088591A (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
HK40063531A (en) Afabicin formulation, method for making the same
HK40063531B (en) Afabicin formulation, method for making the same
JPH11246392A (ja) 経口用固形製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250715